Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

as designated an orphan medicinal product on October 8, 2009. Upon granting of a Centralized Marketing Authorization and retention of the orphan medicinal product designation, Cinryze would be entitled to a period of 10 years market exclusivity in respect of the approved therapeutic indication. This 10-year market exclusivity period could be extended cumulatively to 12 years when the results of all studies conducted in compliance with an agreed pediatric investigation plan are completed and included in the summary of product characteristics.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze was approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the recommended indication is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  <
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... the treatment of cancer and other diseases, announced today ... Administration (CFDA) has approved the Company,s application to conduct ... (TNBC) patients in China for ... Ken K. Ren , Ph.D., CASI,s Chief Executive Officer, ...
(Date:7/21/2014)... , July 22, 2014 Research and ... of the "Global Coronary Stents Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 A coronary stent is a ... of stainless steel, cobalt-based alloy with mechanism of ... blockages that may occur in patients after they ...
(Date:7/18/2014)... July 18, 2014  Patient engagement is a ... marketing is one of the principal groups that ... Policy groups within the pharmaceutical industry are among ... activities and initiatives to positively impact the "patient ... firm, Best Practices, LLC, identified the key support ...
Breaking Medicine Technology:CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo 2Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo 3Government Affairs & Public Policy Groups Playing Critical Role in Patient Engagement, Reports Best Practices, LLC 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and ... Sachs Global Healthcare Conference on Tuesday, June 15 , at ... Los Angeles .  The presentation will be webcast on the following ... , ...
... Epocal, Inc., a leading edge provider of point ... Food and Drug Administration (FDA) clearance to market its new ... from the epoc System are used to evaluate acid-base status ... acidity of the blood).  The addition of lactate to the ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2
(Date:7/21/2014)... 22, 2014 Recently, Stwd.co.uk, a popular supplier ... wedding dresses. Additionally, the company’s chief executive officer has stated ... prices, up to 58% off. , “All our new and ... offer is launched to bring huge benefits to worldwide customers. ... cheap wedding outfits. By the way, we offer custom made ...
(Date:7/21/2014)... PowerObjects, a professional services firm 100% ... for Microsoft Dynamics CRM, has joined the prestigious ... of the most strategic Microsoft Dynamics partners from ... them in the highest echelon of the Microsoft ... Microsoft Dynamics Inner Circle have performed to a ...
(Date:7/21/2014)... (Philadelphia, PA) Patients who have a clot ... be treated with traditional blood-thinning medication or undergo ... comfortable that there is no difference in death ... more bleeding risks with the catheter procedure, according ... Medicine researchers. The study involved a review of ...
(Date:7/21/2014)... July 21, 2014 (HealthDay News) -- The "viral reservoir" ... detection and elimination, is established much earlier than previously ... new obstacles for those working to eradicate the AIDS-causing ... HIV Research Program. They said the presence of the ... a cure for a subtype of HIV, known as ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
Breaking Medicine News(10 mins):Health News:2014 Cheap Wedding Dresses, Newest Items Offered by Professional Company Stwd.co.uk 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2
... the experts are happy about the significant improvement in ... discovery of a new virus carried by bats ... ,Health and veterinary experts have singled out Indonesia, ... bird flu contagion is particularly worrisome. ,FAO's ...
... that a proud person could either be truly self-confident ... California study demonstrated that people have a propensity to ... authors term authentic pride, or they link it to ... ,While authentic pride was connected to more positive personality ...
... technique, called coherent anti-Stokes Raman cattering ... sclerosis. ,The researchers have studied ... the technique. ,Myelin is the fatty sheath coating ... efficient nerve fibre conduction. In diseases such as multiple sclerosis, ...
... there's one person who's still not convinced that Britney Spears is ... her soon to be ex-hubby Kevin Federline. ,A ... Britney is 'mentally unstable', and the reason behind her breakdown earlier ... ,"He thinks she's mentally unstable and too young to ...
... correction for clubfoot, a birth defect in which the foot ... compliance and fewer complications than the traditional brace used to ... professor of orthopedic surgery at the School of Medicine, designed ... active movement, preserve muscle strength in the foot and ankle ...
... cell startlingly similar to its human counterpart will likely ... organ tissue in people, two studies reported Wednesday. ... the inner-most layer of week-old rodent embryos, will provide ... diseases and injuries, the researchers said. ,"They ...
Cached Medicine News:Health News:Avian Flu Seen in Others Birds too 2Health News:Avian Flu Seen in Others Birds too 3Health News:Pride, Even the Hubristic Kind, Allows Us to Survive 2Health News:New Innovation in Clubfoot Treatment 2Health News:New Innovation in Clubfoot Treatment 3Health News:'Missing Link' Stem Cells may Shorten Path to Therapies 2Health News:'Missing Link' Stem Cells may Shorten Path to Therapies 3
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: